OTC:PETV
PetVivo Holdings, Inc.
PetVivo Holdings develops innovative nutritional supplements and health solutions for companion animals, aiming to capitalize on the booming global pet care market.
Key Metrics
Investment Thesis
Bull Case
Investors might consider PETV for its aggressive growth strategy in the lucrative pet care sector, where revenue grew 33% over the last two years while maintaining a robust cash balance of $227k. The company's heavy investment in R&D and operating intangibles suggests a long-term potential to disrupt the market with proprietary products that currently lack competition. If management can successfully scale operations and reduce G&A costs, the current negative earnings could quickly flip into significant profitability given the high-margin nature of supplement businesses.
Bear Case
The stock is risky due to its deep burn rate, evidenced by a $-8.4M net loss and negative operating cash flow that has persisted for five consecutive years. Management's reliance on dilutive financing events like share issuances ($2.1M) to fund operations suggests an unsustainable path without a major breakthrough in revenue growth or cost control. With current liabilities exceeding current assets and a massive retained earnings deficit, the company faces imminent solvency risks if it cannot generate positive cash flow soon.
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. (PETV) is a growth-stage biotechnology and pet care company focused on developing innovative nutritional supplements and health solutions for companion animals. The company serves the expanding global pet industry by leveraging research and development to create premium products that address specific animal health needs. With recent investments in operating intangibles and R&D, PetVivo aims to transition from a loss-making startup to a profitable market leader in the pet wellness sector.
Analysis
Management Discussion
While PetVivo maintained a slight revenue increase to $1.1M in 2025 compared to $1.0M the prior year, profitability remains elusive with net losses fluctuating between $-8.4M and $-11.0M over the last three years. Cash flow from operations turned negative at $-5.3M despite non-cash adjustments of $3.0M, suggesting that current business activities are not generating sufficient liquidity to cover operating expenses and capital expenditures. The heavy reliance on financing cash flow ($6.0M) and share issuances ($2.1M) highlights the company's dependence on external capital to sustain its high-burn business model.
Industry Overview
The global pet care industry is experiencing rapid expansion driven by humanization trends where consumers treat pets like family members, willing to spend premium prices on health and wellness products. However, this sector is also becoming increasingly crowded with established players and new entrants, intensifying competition for market share and pricing power. Companies in this space must continuously innovate through R&D to differentiate their offerings, a challenge that requires significant upfront capital investment like PetVivo is currently undertaking.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $917.2K | $968.7K | $1.1M |
| Cost of Revenue | $526.8K | $229.2K | $137.7K |
| Gross Profit | $390.3K | $739.5K | $994.9K |
| Operating Expenses | $9.1M | $11.4M | $9.1M |
| Operating Income | $-8.7M | $-10.6M | $-8.1M |
| R&D | $690.6K | $1.3M | $1.6M |
| G&A | $5.0M | $6.7M | $4.8M |
| Marketing | $3.4M | $3.4M | $2.6M |
| Stock-Based Comp | $1.5M | $2.1M | $1.1M |
| D&A | $114.4K | $126.8K | $174.6K |
| Depreciation | $104.6K | $118.3K | $118.2K |
| Amortization | $9.8K | $8.6K | $6.4K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $15.8K | $-334.0K | $-343.4K |
| Pre-Tax Income | $-8.7M | $-11.0M | $-8.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-8.7M | $-11.0M | $-8.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-8.7M | $-11.0M | $-8.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-8.7M | $-11.0M | $-8.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $1.4M | $1.0M | $5.6M |
| Cash & Equivalents | $475.3K | $87.4K | — |
| Accounts Receivable | $86.7K | $18.7K | $60.6K |
| Inventory | $370.3K | $390.1K | $323.5K |
| Prepaid Expenses | $491.7K | $545.5K | $447.8K |
| Other Current Assets | $0 | $0 | $4.8M |
| Long-Term Assets | $1.0M | $2.1M | $3.7M |
| PP&E (Net) | $630.9K | $821.7K | $766.9K |
| Operating Leases | $318.0K | $1.2M | $961.5K |
| Other LT Assets | $66.1K | $57.6K | $2.0M |
| Total Assets | $2.4M | $3.1M | $9.3M |
| Current Liabilities | $1.5M | $1.4M | $4.3M |
| Accounts Payable | $588.7K | $821.2K | $821.1K |
| Current Leases | $78.1K | $190.6K | $163.8K |
| Other Current Liab | $6.9K | $157.5K | $2.4M |
| Long-Term Liabilities | $260.2K | $1.0M | $803.1K |
| LT Operating Leases | $239.8K | $1.0M | $797.7K |
| Other LT Liab | $20.4K | $13.2K | $5.4K |
| Total Liabilities | $1.7M | $2.4M | $5.1M |
| Shareholders' Equity | $725.0K | $686.0K | $4.2M |
| Paid-In Capital | $72.4M | $83.5M | $95.4M |
| Retained Earnings | $-71.8M | $-82.8M | $-91.2M |
| Total L&E | $2.4M | $3.1M | $9.3M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-8.7M | $-11.0M | $-8.4M |
| Non-Cash Adjustments | $1.2M | $3.5M | $3.0M |
| Working Capital Changes | $683.3K | $-8.6K | $33.1K |
| Cash from Operations | $-6.8M | $-7.4M | $-5.3M |
| Capital Expenditures | $423.9K | $309.1K | $63.4K |
| Cash from Investing | $-423.9K | $-309.1K | $-563.4K |
| Cash from Financing | $1.6M | $7.3M | $6.0M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-5.6M | $-387.9K | $140.3K |
| Beginning Cash | $6.1M | $475.3K | $87.4K |
| Ending Cash | $475.3K | $87.4K | $227.7K |
Frequently Asked Questions
How does PetVivo Holdings, Inc. make money?
1) Innovative Pet Nutrition & Supplements: Revenue derived from selling specialized health-focused products targeting specific animal needs. 2) Research & Development Operations: Significant spending allocated to R&D ($1.6M) and operating intangibles ($500k) indicating a focus on product pipeline growth. 3) Corporate & General Administration: High overhead costs driven by G&A expenses ($4.8M), marketing ($2.6M), and share-based compensation ($1.1M) typical of early-stage biotech ventures.
What are the main risks for PETV?
1) Persistent Losses and Cash Burn: The company recorded a net loss of $-8.4M in 2025 with negative cash flow from operations ($-5.3M), raising concerns about runway and ability to reach profitability without further dilution. 2) High Operating Leverage and Overhead: General and administrative expenses ($4.8M) and marketing spend ($2.6M) are disproportionately high relative to revenue ($1.1M), creating significant fixed cost pressure. 3) Liquidity Constraints: The company carries substantial long-term liabilities ($803k) and a retained earnings deficit of $-91.2M, indicating limited financial flexibility to weather market downturns.
What is PETV's competitive advantage?
1) Proprietary Product Pipeline: Heavy investment in R&D suggests a strategy to build a portfolio of unique, patented pet health formulations with high switching costs for consumers. 2) First-Mover Potential in Niche Segments: The company focuses on specific animal needs rather than commoditized food, potentially capturing higher margins in underserved market niches. 3) Scalable Intangible Assets: Significant capital allocation to operating intangibles ($500k) indicates the early stages of building valuable brand equity and intellectual property assets.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.